Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2007

Medtronic Makes $3.75M Equity Investment in NanoCor

  • Medtronic invested $3.75 million in NanoCor Therapeutics to help the company advance its gene-based drug for congestive heart failure (CHF). In return, Medtronic holds the right to exclusively license this product and to develop the associated delivery technologies for central nervous system diseases.

    Medtronic reports that it will invest an additional $3.75 million upon NanoCor meeting certain milestones.

    NanoCor’s treatment consists of the delivery of a gene developed at the Massachusetts General Hospital and the University of Cincinnati. NanoCor is an affiliate of Asklepios BioPharmaceutical and will use AskBio’s Biological NanoParticle and Self-Complementary vector technologies that are derived from human adeno-associated virus vectors for delivery.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »